About the Hip & Knee Osteoarthritis Working Group

Osteoarthritis (OA) is one of the most common musculoskeletal diseases, with an estimated prevalence of 12% to 22% worldwide. It is the leading cause of disability among older adults, with an estimated lifetime risk of knee OA about 40% in men and 47% in women.

Clinical trials seek to determine whether treatments are safe and beneficial for patients by comparing their relative effects on outcomes chosen to identify benefit or harm. The results can then be used to make decisions on whether a treatment under investigation should be recommended. It is, therefore, essential that outcomes reported in trials are those needed by decision makers, and reflect meaningful measures for patients, clinicians, and others.

Philip Conaghan

Phil Conaghan

Co-Chair

Gillian Hawker

Gillian Hawker

Co-Chair

David Hunter

David Hunter

Co-Chair

Lyn March

Lyn March

Co-Chair

toby smith

Toby Smith

Fellow

OMERACT Endorsed Core Domain Set for Hip & Knee Osteoarthritis

Screen Shot 2021-02-22 at 2.37.26 PM

Working Group Members:

Roy Altman
Jennifer Anderson
Nigel Arden
Anne Ashford
Nicholas Bellamy
Maarten Boers
Thomas Buttel
Robin Christensen
Phil Conaghan
Maarten de Wit
Maxime Dougados
Francis Guillemin
Gilliam Hawker

David Hunter
Marc Hochberg
Ulrike Kaiser
Gurdyal Kalsi
Margreet Kloppenburg
Christoph Ladel
Marissa Lassere
Richard Loeser
Lyn March
Ali Mobasheri
Tuhina Neogi
Thao Pham

Ewa Roos
Thomas Schnitzer
Bev Shea
Lee Simon
Toby Smith
Vibeke Strand
Alan Tennant
Caroline Terwee
Peter Tugwell
Desiree van der Heijde
Paula Williamson
Thasia Woodworth

Scroll to Top